Effect of HIV Infection on Atypical Squamous Cells of Undetermined Significance
|
|
- Austin Hancock
- 6 years ago
- Views:
Transcription
1 MAJOR ARTICLE HIV/AIDS Effect of HIV Infection on Atypical Squamous Cells of Undetermined Significance Ann Duerr, 1 Pangaja Paramsothy, 2 Denise J. Jamieson, 3 Charles M. Heilig, 3 Robert S. Klein, 4 Susan Cu-Uvin, 5 Paula Schuman, 6 and Jean R. Anderson, 7 for the HIV Epidemiology Research Study 1 Fred Hutchinson Cancer Research Center, Seattle, Washington; 2 Contraceptive Research and Development, Arlington, Virginia; 3 Centers for Disease Control and Prevention, Atlanta, Georgia; 4 Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, 5 Brown Medical School, Providence, Rhode Island, 6 Wayne State University School of Medicine, Detroit, Michigan, and 7 Johns Hopkins University School of Medicine, Baltimore, Maryland Background. Detection of atypical squamous cells of undetermined significance (ASCUS) is a cervical cytologic finding that is suggestive but not definitive of squamous intraepithelial lesions (SILs). Methods. We examined the risk, characteristics, and progression of ASCUS in with and without human immunodeficiency virus (HIV) infection. Cervical Papanicolou (Pap) test and colposcopy data were obtained at the first 10 semiannual visits for the HIV Epidemiology Research study of 774 and 480 demographically similar, HIV-uninfected in the United States. Multiple logistic regression models and Cox proportional hazards models were utilized. Results. ASCUS was more common among (odds ratio [OR], 1.6 [95% confidence interval {CI}, ] to 2.6 [95% CI, ]) after adjustment for human papillomavirus (HPV) infection and other risk factors (e.g., race, condyloma, and prior Pap test result). Among with normal Pap test results at enrollment, the cumulative incidence of ASCUS was 78% among and 38% among HIVuninfected. and HIV-uninfected with ASCUS did not differ by prevalence of indices of inflammation (inflammation on Pap test and leukocytes on cervical gram stain). HPV infection, including high risk types, was more common among with ASCUS. Among with ASCUS, 60% of and 25% of HIV-uninfected developed SILs ( P!.01 ). Compared with with higher CD4 + lymphocyte counts, with CD4 + lymphocyte counts!200 cells/ml were more likely to present subsequently with a SIL detected by Pap test (OR, 1.7; 95% CI, ). Conclusions. Higher risk of SIL following the appearance of ASCUS among, especially with low CD4 + lymphocyte counts, supports the need for follow up with colposcopy and histologic examination, as indicated, to allow early detection and treatment of SIL. Both the etiology and outcome of atypical squamous cells of undetermined significance (ASCUS) detected by cervical cytologic testing are uncertain, as the name implies. Although it is recommended that laboratories avoid this diagnosis when a more precise diagnosis can be given [1], the inflammatory and predysplastic changes that lead to a diagnosis of ASCUS are typically reported in 5% 10% of Papanicolaou (Pap) tests [2 4]. For some, ASCUS may be an indication of coexisting dysplasia. Moreover, a diagnosis of ASCUS Received 12 August 2005; accepted 22 November 2005; electronically published 10 February Reprints or correspondence: Dr. Ann Duerr, 1100 Fairview Ave. N. LE-500, P.O. Box 19024, Seattle, Washington (aduerr@fhcrc.org). Clinical Infectious Diseases 2006; 42: by the Infectious Diseases Society of America. All rights reserved /2006/ $15.00 may be the result of early cytologic findings in eventually diagnosed with severe dysplasia, with more than one-third of cases of biopsy-proven cervical intraepithelial neoplasia being associated at the preceding Pap test with ASCUS, rather than with squamous intraepithelial lesions (SILs) [3]. Current management guidelines [6] propose follow-up of ASCUS using any of the following methods: repeat cytological testing, colposcopy, or DNA testing for high-risk human papillomavirus (HPV) types. Referral for colposcopy is recommended for all with ASCUS. These guidelines recommend referral for colposcopy for all with ASCUS when high-grade SIL cannot be ruled out. ASCUS remains an incompletely described entity among HIV-uninfected, even more so among. In contrast, the increased risk of HIV/AIDS CID 2006:42 (15 March) 855
2 SIL among has been well documented, and several groups [7, 8] have reported the increased risk of progression of SIL in this population. Fewer studies have reported on ASCUS [5]. Because there are few data on the comparative prevalence of ASCUS among and HIVuninfected and on the risk of cervical intraepithelial neoplasia among with ASCUS, it is difficult to know whether current management algorithms for ASCUS are optimal for. Using data from a large prospective study, we examined AS- CUS in and HIV-uninfected with similar risk profiles. We looked specifically at whether the risk or characteristics of ASCUS differ between the 2 groups and whether HIV infection alters the risk of subsequent progression to SIL among with ASCUS. METHODS The HIV Epidemiology Research Study enrolled 1310 (871 and 439 at-risk, HIV-uninfected ) from 4 US cities (Bronx, NY; Baltimore, MD; Providence, RI; and Detroit, MI) between April 1993 and January 1995; details of the design and enrollment procedures have been reported [9]. Institutional review boards approved the study protocol at each site and at the Centers for Disease Control and Prevention; all participants gave written, informed consent. Each site contributed approximately one-fourth of the participants. HIVinfected without AIDS-defining conditions and HIVuninfected were selected in such a way that about one-half reported risk related to injection drug use, and the remainder had increased risk due to sexual behavior but not injection drug use. Pap tests were performed with a cytobrush and a wooden spatula on all with a cervix. All Pap test results were evaluated using predefined criteria [10; an expansion of the 1988 Bethesda scoring system for cervical cytology] by a single commercial cytologic laboratory (Kyto Diagnostics, New York) [11, 12]. At 1 study site (Baltimore), cervical colposcopy was performed routinely at each study visit; at the other 3 sites, were referred for colposcopy if they had 1 Pap test result showing SIL or 2 consecutive Pap test results showing ASCUS. Cervical and/or vaginal secretion specimens and exfoliated cells were collected by cervicovaginal lavage and tested for HPV using PCR [9 11]. The gynecologic exam also ascertained the presence of infectious and inflammatory conditions, discharge, visible ulcers, and condylomata. Gram stains of cervical secretion specimens were scored for the presence of polymorphonuclear leukocytes, monocytes, and bacteria. Gram stains of vaginal secretion specimens were scored for bacterial vaginosis and for the presence of yeast, sperm, RBCs, polymorphonuclear leukocytes, and monocytes. Trichomoniasis was initially defined using wet mount (at visits 1 3); culture in modified Diamond s medium was introduced for all at visit 4. Women with symptomatic vaginal or cervical infections were either treated or referred for treatment. HIV infection status was ascertained through ELISA and Western blotting, with assessment of immune system compromise using CD4 + cell counts, as described elsewhere [13]. HIV load was determined via a third-generation, branched DNA signal amplification assay (Chiron) with a lower quantification limit of 50 copies/ml. Antiretroviral use was ascertained by self-reporting; treatment regimens were classified as HAART, other antiretroviral therapy, or no antiretroviral therapy. Regimens not listed in published guidelines [14] were classified as HAART if they were believed to have a high likelihood of effective and sustained viral suppression. Statistical methods. Pearson s x 2 test or Fisher s exact tests were used to compare proportions, and Student s t test was used to compare means between groups. The Wilcoxon ranksum test was used for variables that were not normally distributed. The cumulative incidence of ASCUS was estimated over the course of this study using the product-limit survival estimator. Logistic models provided estimates of overall prevalence by means of methods that compensated for within-subject correlation across multiple observations. These prevalence estimates averaged the characteristics of participants over the course of the study. Multiple logistic regression models that corrected for repeated measures were used to identify correlates of abnormal cervical cytologic findings. Initial models examined covariates one at a time and adjusted for repeated measures and 2 design variables: study site and risk category (sexual behavior or injection drug use). Factors suggesting at least a moderate ( P!.2) association with ASCUS were included in the subsequent models. Interaction between HIV and other covariates was assessed and included if P!.2. Inferences were based on SEs estimated by robust methods using an m-dependent working correlation structure. Cox proportional hazard models were used to calculate hazard ratios for the risk of ASCUS in with normal Pap test results at baseline, as well as the risk of SIL in with Pap test results showing ASCUS at baseline. Factors suggesting at least a moderate ( P!.2) association with the outcome were included in the subsequent models. The multivariate model also included the design variables study site and risk category. Interaction between HIV and other covariates was assessed and included if P!.2. All calculations were performed using SAS software, version 8.2 (SAS Institute). 856 CID 2006:42 (15 March) HIV/AIDS
3 Table 1. Inflammation and HPV infection among with atypical squamous cells of undetermined significance (ASCUS). Among No. (%) of visits Among HIV-uninfected Inflammation detected by Pap test 175 (15) 57 (20).28 Inflammation with cellular change detected by Pap test 49 (4.2) 15 (15).23 Mononuclear cell count b.53!1 642 (82) 152 (78) (10) 24 (12) 3 64 (8) 18 (9) PMN count b.93!1 247 (32) 59 (30) (23) 42 (22) (22) 39 (20) (24) 54 (28) HPV infection status determined by hybrid capture c!.01 Infected 522 (58) 59 (24) Uninfected 376 (42) 185 (76) HPV risk type determined by PCR!.01 High 260 (23) 39 (14) Intermediate 267 (24) 34 (12) Low 188 (17) 19 (7) Untypeable 196 (17) 44 (16) Not available 217 (19) 146 (52) Histologic finding d.33 Normal biopsy and normal colposcopy results 138 (81) 37 (80) CIN I 31 (18) 2 (4) CIN not otherwise specified 2 (1) 7 (15) NOTE. HPV, human papillomavirus; Pap, Papanicolou; PMN, polymorphonuclear leukocytes. a Multiple logistic regression models were used to adjust for repeated measures. b Determined by cervical Gram staining, which was restricted to visits 1 5 for with ( n p 782) and without ( n p 194) HIV infection. Data are no. of cells per 5 oil immersion fields. c Restricted to 898 visits among and 244 visits among HIV-uninfected. Samples that tested positive for any HPV type by hybrid capture were considered to demonstrate infection; samples that tested negative or indeterminate by hybrid capture or negative by PCR were considered to demonstrate noninfection. d Restricted to from 1 study site where colposcopy was routinely performed at each visit, regardless of Pap test result. P a RESULTS We considered cervical Pap test data from the first 10 semiannual study visits (over a period of up to 4.7 years) and included results from 8185 Pap tests. Data were available for 795 and 404 HIV-uninfected (N p 1199) with intact cervices at baseline. A median follow-up time of 4.4 years did not differ by HIV serostatus. At enrollment, were more likely to be African American and were less likely to have finished high school. For the 6 months prior to enrollment, were more likely to have reported always using a condom, less likely to have reported using crack, less likely to have reported having 11 male sexual partner than HIV-uninfected. HIVinfected and HIV-uninfected did not differ by the following factors at enrollment: risk cohort (drug use or sexual behavior), age, income, number of live births, smoking (currently), exchange of sex for drugs or money, injection drug use, and number of female sex partners (in the previous 6 months). Characteristics of ASCUS. In general, markers of cervical inflammation observed on Pap tests or on cervical specimens collected concurrently were of similar frequency among HIVinfected and HIV-uninfected with ASCUS (table 1). The presence of vaginal infections that might affect Pap test HIV/AIDS CID 2006:42 (15 March) 857
4 Table 2. Factors associated with atypical squamous cells of undetermined significance (ASCUS) versus normal Papanicolaou (Pap) test result. Adjusted OR (95% CI) a All (N p 1199) (n p 795) HIV status and cervical ectopy, cervical ectopy 2.6 ( ) 1.7 ( ), no ectopy 1.6 ( ) 1.0 b HIV-uninfected, cervical ectopy 0.9 ( ) HIV-uninfected, no ectopy 1.0 b CD4 + cell count, cells/ml! ( ) ( ) b HIV load, copies/ml 150, ( ) 10,001 50, ( ) , ( ) ( ) Undetectable 1.0 b Current HAART use c HAART 1.4 ( ) Other antiretroviral use 1.2 ( ) No antiretroviral use 1.0 b HPV risk type determined by PCR High 5.1 ( ) 5.4 ( ) Intermediate 4.0 ( ) 4.0 ( ) Low 2.4 ( ) 2.6 ( ) Untypeable 2.1 ( ) 1.9 ( ) No types detected 1.0 b 1.0 b Trichomoniasis present 0.8 ( ) 0.7 ( ) Cervical, vulvar, or vaginal condyloma 1.3 ( ) 1.3 ( ) Race and/or ethnicity African American 0.7 ( ) 0.7 ( ) Hispanic 0.8 ( ) 0.7 ( ) Other 0.7 ( ) 0.2 ( ) White 1.0 b 1.0 b No. of male sex partners within the previous 6 months ( ) 0.9 ( ) ( ) 0.8 ( ) b 1.0 b Pap test result at last visit SIL 12.6 ( ) 11.4 ( ) ASCUS 6.7 ( ) 5.8 ( ) Normal 1.0 b 1.0 b NOTE. Multiple logistic regression models that corrected for repeated measures were used to calculate ORs. HPV, human papillomavirus; SIL, squamous intraepithelial lesion. a ORs are adjusted for all other risk factors in the table, as well as for study site, risk cohort, and repeated measures. b Referent. c As defined by the Department of Health and Human Services guidelines.
5 Figure 1. Data shown for with normal Papanicolaou (Pap) test results at enrollment. The cumulative incidence of atypical squamous cells of undetermined significance (ASCUS) was 78% among and 38% among HIV-uninfected ( P!.01). Kaplan-Meier and product limit estimator method were utilized. results also did not differ markedly according to status of HIV infection. with ASCUS were more likely to be colonized with Candida species than were HIV-uninfected (36.7% of visits vs. 27.5% of visits; P!.01), but they did not differ in the presence of the following 2 vaginal infections: bacterial vaginosis (42.1% vs. 40.4%; P p.64) and trichomoniasis (15.1 vs. 13.2%; P p.43) (data not shown). HPV infection, including infection caused by high-risk virus types, was more common among with ASCUS than it was among HIV-uninfected with ASCUS (P!.01). Despite this, routine colposcopy performed for all HIVinfected and HIV-uninfected at 1 site did not reveal a higher prevalence of aceto-white, punctation, mosaicism, or atypical vessels among with ASCUS (data not shown). with ASCUS did not have a higher prevalence of cervical intraepithelial neoplasia (table 1). Prevalence of and risk factors for ASCUS. Although the characteristics of ASCUS appeared not to differ according to status of HIV infection, it was more common in both at the baseline visit (adjusted prevalence ratio, 1.6; 95% CI, ) and during the follow-up period. For all, the multivariate model presented (table 2) contains all variables found in initial analyses to be significantly associated with the risk of ASCUS ( P!.2). Factors examined in initial analyses and not found to be significantly associated with ASCUS included age, education, number of pregnancies or live births, recent sex with a woman (during the previous 6 months), condom use (during the previous 6 months), ever having exchanged sex for drugs or money, injection drug use, douching, vaginal colonization with Candida species, and bacterial vaginosis. In the final adjusted model for all, ASCUS was associated with HIV infection; cervical ectopy present during physical exam; cervical, vaginal, and/or vulvar condyloma present during physical exam; HPV infection; race and/ or ethnicity; and Pap test result from the previous visit. The association between ASCUS and HIV infection was modified by the presence of cervical ectopy. In the multivariate model of (table 2, right column), the level of ASCUS was significantly elevated in with CD4 + cell counts!200 cells/ml (adjusted OR, 1.5; 95% CI, ). Risk of developing ASCUS. Compared with HIV-uninfected, were more likely to present with ASCUS after receiving a normal Pap test result (figure 1). Among the 426 and 275 HIV-uninfected with normal Pap test results at enrollment, the cumulative incidence of ASCUS was 78% among the and 38% among the HIV-uninfected. In a proportional hazards model ( n p 701), the adjusted relative hazard for AS- CUS associated with HIV infection was 1.8 (95% CI, ) (table 3). HPV risk type at baseline was also associated with increased risk of progression to ASCUS. The hazard ratio of high-risk and intermediate-risk type was 3.2 (95% CI, ). For low-risk and untypable HPV, the hazard ratio was 1.6 (95% CI, ). Women who were culture positive for Candida species at baseline were also at risk. There was no statistical evidence of interaction between HIV infection and any other risk factor in the model. Among, those with CD4 + cell counts!200 cells/ml had a hazard ratio of 1.9 (95% CI, ). If ASCUS was defined as findings of ASCUS on 2 consecutive Pap tests, the cumulative incidence was reduced (27% and 7% in and HIV-uninfected Table 3. Risk of atypical cells of undetermined significance for with normal Papanicolaou test results at baseline. Adjusted hazard ratio (95% CI) All (n p 701) (n p 426) HIV infected 1.8 ( ) CD4 + cell count, cells/ml! ( ) ( ) a HPV risk type High or intermediate 3.2 ( ) 3.1 ( ) Low or untypeable 1.6 ( ) 1.8 ( ) No type detected 1.0 a 1.0 a Culture positive for Candida species 1.3 ( ) b 1.4 ( ) NOTE. Cox proportional hazard models were used to calculate hazard ratios. Models were also adjusted for the study-design variables site and risk cohort. HPV, human papillomavirus. a Referent. b P p.029. HIV/AIDS CID 2006:42 (15 March) 859
6 Figure 2. Data shown for with atypical squamous cells of undetermined significance (ASCUS) detected by Papanicolaou (Pap) test at the enrollment visit. The cumulative incidence of squamous intraepithelial lesion (SIL) was 60% among and 25% among HIV-uninfected ( P!.01). Kaplan-Meier and product limit estimator method were utilized., respectively), but the associations seen did not change (data not shown). Progression of ASCUS. Among with ASCUS at the enrollment visit (148 of whom were HIV infected and 48 of whom were HIV uninfected; figure 2), the cumulative incidence of SIL, according to Pap test results, was 60% among HIVinfected and 25% among the HIV-uninfected ( P!.01). Among with ASCUS at baseline who developed SIL during the follow-up period, the median time to SIL was 12 months among and 18 months among HIV-uninfected. Among with ASCUS at baseline, were at 2.4 times the risk of subsequently presenting with SIL, compared with HIV-uninfected. Women with high- or intermediate-risk types of HPV were significantly more likely to later present with SIL than were with no HPV present (table 4). DISCUSSION This study found that, particularly those with low CD4 + cell counts, were more likely to develop ASCUS, according to Pap test results. with ASCUS were more likely to present subsequently with cytological evidence of SIL, particularly with low CD4 + cell counts. We found that, among, increased risk of ASCUS demonstrated by Pap test and increased risk of SIL were associated with infection with high- or intermediate-risk types of HPV. A longitudinal analysis from the Women s Interagency HIV Study [15] found that, among with normal Pap test results at baseline, a greater proportion of (73.0%) than of HIV-uninfected (42.3%) had at least 1 abnormal Pap test result during up to 5 years of follow up, and 30% of all had ASCUS as a Pap test finding during this time period. In contrast to our findings, the reported prevalence of ASCUS in the Women s Interagency HIV Study did not vary significantly by status of HIV infection. By contrast, a greater proportion of in the study had low-grade SIL, compared with HIV-uninfected. ASCUS, the most common abnormal finding by Pap test, is not reliably reproducible among cytopathologists. ASCUS has been used in the Bethesda cytological classification system to indicate abnormal squamous cells that do not meet (quantitatively or qualitatively) criteria for a diagnosis of SIL [16]. Although the majority of Pap tests demonstrating ASCUS probably reflect a benign, reactive process, they may also reflect either underlying histologic abnormalities, or they may herald the future development of a histologic abnormality. With respect to management, the current guidelines state that the following 3 algorithms are considered to be acceptable for with ASCUS: repeat cytological examination, HPV DNA testing, and colposcopy [6]. By contrast, for with ASCUS for whom high-grade SIL cannot be ruled out, referral for colposcopy is the only recommended option. For, referral for colposcopy is recommended, regardless of immune status, despite limited evidence that addresses the appropriateness of this recommendation. Few studies have compared the incidence of ASCUS and the risk of SIL after an ASCUS Pap test among. The strengths of the present study include the large number of who were observed; the fact that the cohorts of HIV- Table 4. Risk of squamous intraepithelial lesion for with atypical cells of undetermined significance (ASCUS) detected by Papanicolaou test at baseline. Adjusted hazard ratio (95% CI) All (n p 196) (n p 148) HIV infected 2.4 ( ) CD4 + cell count, cells/ml! ( ) ( ) a HPV risk type High or intermediate 2.4 ( ) 2.4 ( ) Low or untypeable 1.6 ( ) 1.6 ( ) No type detected 1.0 a 1.0 a NOTE. Cox proportional hazard models were utilized to calculate hazard ratios. Models were also adjusted for the study-design variables site and risk cohort. HPV, human papillomavirus. a Referent. 860 CID 2006:42 (15 March) HIV/AIDS
7 infected and HIV-uninfected resembled each other with respect to HIV risk, and demographic characteristics; the long follow-up period with frequent collection of data regarding sexual behavior, and gynecological outcomes, and other medical history. This study s limitations include the fact that data were not available on the subclassification of ASCUS as ASC-US (atypical squamous cells undetermined significance) and ASC- H (atypical squamous cells cannot exclude high-risk squamous intraepithelial lesion [HS12]), in accordance with the most recent classification system, mainly because data collection was completed by Another limitation is the inclusion of colposcopic and histologic data for only a subset of study participants. Our finding that with ASCUS are more likely than seronegative to progress to SIL provides empirical support for the current recommendation that undergo colposcopic evaluation, with histologic examination as indicated, after the first finding of ASCUS. HIV EPIDEMIOLOGY RESEARCH STUDY GROUP Robert S. Klein, Ellie Schoenbaum, Julia Arnsten, Robert D. Burk, Chee Jen Chang, Penelope Demas, and Andrea Howard (Montefiore Medical Center and the Albert Einstein College of Medicine); Paula Schuman and Jack Sobel (Wayne State University School of Medicine); Anne Rompalo, David Vlahov, and David Celentano (Johns Hopkins University School of Medicine); Charles Carpenter and Kenneth Mayer (Brown University School of Medicine); Ann Duerr, Lytt I. Gardner, Charles M. Heilig, Scott Holmberg, Denise Jamieson, Jan Moore, Ruby Phelps, Dawn K. Smith, and Dora Warren (Centers for Disease Control and Prevention); and Katherine Davenny (National Institute of Drug Abuse). Acknowledgments Financial support. Centers for Disease Control and Prevention (U64/ CCU106795, U64/CCU206798, U64/CCU306802, and U64/CCU506831). Potential conflicts of interest. All authors: no conflicts. References 1. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995; 172: Kinney WK, Manos MM, Hurley LB, Ransley JE. Where s the highgrade cervical neoplasia? The importance of minimally abnormal papanicolaou diagnoses. Obstet Gynecol 1998; 91: Wright TC Jr, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of with low-grade cytologic abnormalities. Obstet Gynecol 1995; 85: Holcomb K, Abulafia O, Matthews RP, et al. The significance of ASCUS in HIV-positive. Gynecol Oncol 1999; 75: Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ Consensus guidelines for the management of cervical cytologic abnormalities. JAMA 2002; 287: Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in. JAMA 2000; 283: Schuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV) seropositive and at-risk HIV-seronegative. J Infect Dis 2003; 188: Smith DK, Warren DL, Vlahov D, et al. Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US. Am J Epidemiol 1997; 146: National Cancer Insitute Workshop. The 1988 bethesda system for reporting cervical/vaginal cytological diagnoses. JAMA 1989; 262: Duerr A, Kieke B, Warren D, et al. Human papillomavirus associated cervical cytologic abnormalities among with or at risk of infection with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184: Jamieson DJ, Duerr A, Burk R, et al. Characterization of genital human papillomavirus infection in who have or who are at risk of having HIV infection. Am J Obstet Gynecol 2002; 186: Centers for Disease Control and Prevention Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17): Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Available at: Accessed 21 April Massad LS, Ahdieh L, Benning L, Minkoff H, Greenblatt RM, Watts H. Evolution of cervical abnormalities among with HIV-1: evidence from surveillance cytology in the s interagency HIV study. J Acquir Immune Defic Syndr 2001; 27: Broder S. The Bethesda System for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda Workshop. JAMA 1992; 267: HIV/AIDS CID 2006:42 (15 March) 861
Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
ACTA BIOMED 2007; 78: 36-40 Mattioli 1885 O R I G I N A L A R T I C L E Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
More informationHUMAN PAPILLOMAVIRUS INFECTION IN WOMEN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS
HUMAN PAPILLOMAVIRUS INFECTION IN WOMEN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS XIAO-WEI SUN, M.D., LOUISE KUHN, PH.D., TEDD V. ELLERBROCK, M.D., MARY ANN CHIASSON, DR.P.H., TIMOTHY J. BUSH, B.A.,
More informationPAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE
Arch Iranian Med 2005; 8 (3): 192 196 Original Article PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Fatemeh Ghaemmaghami MD *, Fereshteh Ensani MD**, Nadereh Behtash MD* Ebrahim
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationAbsolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women
Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women 2145 Philip E. Castle, Ph.D., M.P.H. 1 Sholom Wacholder, Ph.D. 1 Mark E. Sherman,
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationInterpersonal Predictors of Depression Trajectories in Women with HIV. Stephanie Milan, Ph.D. University of Connecticut November 3, 2005
Interpersonal Predictors of Trajectories in Women with HIV Stephanie Milan, Ph.D. University of Connecticut November 3, 2005 in Women with HIV Elevated symptoms of depression are common among women with
More informationThe Korean Journal of Cytopathology 13(1): 14-20, 2002
13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous
More informationWIHS HPV Working Group Summary
HPV WIHS HPV Working Group Summary Human papillomavirus (HPV) research has been a major component of the WIHS since the cohort was initiated in 1994. Studies of HPV are essential to addressing the core
More informationHuman Papillomavirus Type 16 and Immune Status in Human Immunodeficiency Virus-Seropositive Women
Human Papillomavirus Type 16 and Immune Status in Human Immunodeficiency Virus-Seropositive Women Howard D. Strickler, Joel M. Palefsky, Keerti V. Shah, Kathryn Anastos, Robert S. Klein, Howard Minkoff,
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationAtypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDevelopment and Duration of Human Papillomavirus Lesions, after Initial Infection
MAJOR ARTICLE Development and Duration of Human Papillomavirus Lesions, after Initial Infection Rachel L. Winer, 1 Nancy B. Kiviat, 2 James P. Hughes, 3 Diane E. Adam, 1 Shu-Kuang Lee, 3 Jane M. Kuypers,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationPrevalence of and Risk Factors for Viral Infections among Human Immunodeficiency Virus (HIV) Infected and High-Risk HIV-Uninfected Women
MAJOR ARTICLE Prevalence of and Risk Factors for Viral Infections among Human Immunodeficiency Virus (HIV) Infected and High-Risk HIV-Uninfected Women Cynthia T. Stover, 1,3 Dawn K. Smith, 2 D. Scott Schmid,
More informationORIGINAL ARTICLES. Utilisation and outcomes of cervical cancer prevention services among HIV-infected women in Cape Town. Methods
Utilisation and outcomes of cervical cancer prevention services among HIV-infected women in Cape Town Priya Batra, Louise Kuhn, Lynette Denny Objective. An audit of outcomes of cervical cancer screening
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationHuman Papillomavirus Prevalence, Viral Load and Cervical Intraepithelial Neoplasia in HIV-Infected Women
BJID 2002; 6 (June) 129 Human Papillomavirus Prevalence, Viral Load and Cervical Intraepithelial Neoplasia in HIV-Infected Women José E. Levi, Maria C.S. Fink, Cynthia L.M. Canto, Nadily Carretiero, Regina
More informationClinical Practice Guidelines June 2013
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
More information9/18/2008. Cervical Cancer Prevention for Adolescent Populations Garcia. Faculty disclosure. Objectives. HPV Positivity by Age (UK)
Faculty disclosure Cervical Cancer Prevention for Francisco, MD, MPH Associate Professor Obstetrics & Gynecology Mexican American Studies Public Health Francisco, MD, MPH has no financial affiliations
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationCase Study 1. Cervical Cancer Screening and Sexually Transmitted Infections Case Studies
Case Study 1 Cervical Cancer Screening and Sexually Transmitted Infections Case Studies Joyce, a 32 year old returning veteran, comes in for a Well Woman visit. She has a history of an abnormal Pap before
More informationANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION
Electronic Journal of Pharmacology and Therapy Vol 4, 15-20 (2011) ISSN: 0973-9890 (Available online at wwwtcrjournalscom) Clinical Article ndexed in: ProQuest database Abstract, USA (ProQuest Science
More informationHPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationHuman Immunodeficiency Virus-Positive Women
Infectious Diseases in Obstetrics and Gynecology 8:176-180 (2000) (C) 2000 Wiley-Liss, Inc. Determinants of Incident Vulvovaginal Candidiasis in Human Immunodeficiency Virus-Positive Women Emma Shifrin,
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationEffect of increasing the frequency of cervical cancer screening among HIV-infected women
The University of Toledo The University of Toledo Digital Repository Master s and Doctoral Projects Effect of increasing the frequency of cervical cancer screening among HIV-infected women Jessica Rae
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationCervical cancer screening in vaccinated population
Cervical cancer screening in vaccinated population Cytology and molecular testing Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol Oncol Izmir, November
More informationCervical Cancer Screening Update. Melissa Hartman, DO Women s Health
Cervical Cancer Screening Update Melissa Hartman, DO Women s Health Previous Cervical Cancer Screening Organization Recommendation ACS (2011) ACP (2008) NCI (2003) Age 21 or 3 years after first intercourse
More informationAnal Intraepithelial Neoplasia in Heterosexual and Homosexual HIV-Positive Men with Access to Antiretroviral Therapy
MAJOR ARTICLE Anal Intraepithelial Neoplasia in Heterosexual and Homosexual HIV-Positive Men with Access to Antiretroviral Therapy T. J. Wilkin, 1 S. Palmer, 2 K. F. Brudney, 3 M. A. Chiasson, 3,5 and
More informationInternational Journal of Biological & Medical Research
Int J Biol Med Res. ; 2(3): 757-761 Int J Biol Med Res www.biomedscidirect.com Volume 2, Issue 3, July BioMedSciDirect Publications Contents lists available at BioMedSciDirect Publications International
More informationAcceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index
DOI 10.1007/s00404-012-2569-y GYNECOLOGIC ONCOLOGY Acceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index Hadi Shojaei Fariba Yarandi Leila
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationINTRODUCTION HSIL AND CERVICAL CARCINOMA IN ASCUS CERVICAL CYTOLOGY
HSIL AND CERVICAL CARCINOMA IN ASCUS CERVICAL CYTOLOGY PREVALENCE OF HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) AND INVASIVE CERVICAL CANCER IN PATIENTS WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationHuman papillomavirus typing in HIV-positive women
Infect Dis Obstet Gynecol ;9:89 93 Human papillomavirus typing in HIV-positive women Meera Hameed, Helen Fernandes, Joan Skurnick, Dorothy Moore, Patricia Kloser 3 and Debra Heller Department of Pathology
More informationCan HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?
Anatomic Pathology / Monitoring HPV-16 Fractions in CIN Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Mary T. Galgano, MD, 1 Philip E. Castle, PhD, MPH, 2 Mark
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationVaginal flora morphotypic profiles and assessment of bacterial vaginosis in women at risk for HIV infection
Infect Dis Obstet Gynecol 2004;12:121 126 Vaginal flora morphotypic profiles and assessment of bacterial vaginosis in women at risk for HIV infection Beth C Tohill 1, Charles M Heilig 1, Robert S Klein
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationHPV, Cervical Dysplasia and Cancer
FACTSHEET HPV, Cervical Dysplasia and Cancer Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions by doctors, may persist and
More informationPSYCHOSOCIAL BURDEN OF ABNORMAL PAP SMEARS AMONG HIV-INFECTED WOMEN AT CHON BURI HOSPITAL, THAILAND
PSYCHOSOCIAL BURDEN OF ABNORMAL PAP SMEARS AMONG HIV-INFECTED WOMEN AT CHON BURI HOSPITAL, THAILAND Mangala PH Jayathunge 1, Chureeratana Bowanwatanuwong 2, Wirach Maek-a-nantawat 1, Benjaluck Phonrat
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationOutcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure
The Korean Journal of Pathology 2012; 46: 359-364 ORIGINAL ARTICLE Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure Joon Seon Song Ilseon
More informationClinical Relevance of HPV Genotyping. A New Dimension In Human Papillomavirus Testing. w w w. a u t o g e n o m i c s. c o m
Clinical Relevance of HPV Genotyping A New Dimension In Human Papillomavirus Testing Human Papillomavirus: Incidence HPV prevalence was 26.8% for women in US aged 14 59 yrs 1 20 million Americans are currently
More informationChapter 14: Role of Triage Testing in Cervical Cancer Screening
Chapter 14: Role of Triage Testing in Cervical Cancer Screening Diane Solomon The classic model of cervical cancer prevention primary screening with cytology, followed by diagnostic colposcopically directed
More informationHPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe. Mark H. Stoler, MD ASC Companion Meeting USCAP 2008
OBJECTIVES: HPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe Mark H. Stoler, MD ASC Companion Meeting USCAP 2008 1. Describe the concept of marker validation in the context of HPV tests. 2. Present
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationLong-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance
Anatomic Pathology / LONG-TERM OUTCOME WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Long-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance Stephen
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationAn Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program
An Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program Susan Baum, MD, MPH NM Nurse Practitioner Council Annual Conference April 20, 2012 I have no commercial relationships related
More informationTrends in Malignancies Among HIV-Infected Patients. Roger Bedimo, MD, MS VA North Texas Health Care System UT Southwestern Medical Center
Trends in Malignancies Among HIV-Infected Patients Roger Bedimo, MD, MS VA North Texas Health Care System UT Southwestern Medical Center Denver, April 2011 Learning Objectives At the conclusion of this
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationNATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN NATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN
NATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN NATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN GLORIA Y.F. HO, PH.D., ROBERT BIERMAN, M.D., LEAH BEARDSLEY,
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More informationThe devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationCervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
More informationPrevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea
RESEARCH COMMUNICATION Prevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea Kidong Kim 1, Jin Ju Kim 2,3, Sun Mie
More informationGenital Dysplasia in Women Infected with Human Immunodeficiency Virus
Genital Dysplasia in Women Infected with Human Immunodeficiency Virus Gregory Taylor, MD, Tracy Wolff, MD, Niharika Khanna, MD, Priscilla Furth, MD, and Patricia Langenberg, PhD* Background: Women infected
More informationEarly Natural History of Incident, Type-Specific Human Papillomavirus Infections in Newly Sexually Active Young Women
Research Article Cancer Epidemiology, Biomarkers & Prevention Early Natural History of Incident, Type-Specific Human Papillomavirus Infections in Newly Sexually Active Young Women Rachel L. Winer 1, James
More informationMEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY
MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationEvaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear
The Korean Journal of Pathology 2010; 44: 528-35 DOI: 10.4132/KoreanJPathol.2010.44.5.528 Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions
More informationHPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION
HPV Vaccine FAST FACTS: Payer & Reimbursement Strategies Medicaid: Many state Medicaid programs cover the HPV vaccine, though this coverage varies by state. Information on coverage can be found through
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More information32 OBG Management May 2015 Vol. 27 No. 5 obgmanagement.com
The Advisory Committee on Immunization Practices recommends routine vaccination against HPV in 11- and 12-year-olds, although the age can range from 9 to 26 years (for those who have not been vaccinated
More informationPatients referred to a colposcopy clinic will often have
The Accuracy of the Papanicolaou Smear in the Screening and Diagnostic Settings Marylou Cárdenas-Turanzas, MD, DrPH, 1 Michele Follen, MD, PhD, 2 Graciela M. Nogueras-Gonzalez, MPH, 1 J.L. Benedet, MD,
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationCan HPV, cervical neoplasia or. HIV transmission?
Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV Jennifer S. Smith Department of Epidemiology pd University of North Carolina Can HPV, cervical
More informationJean Anderson, MD Catherine Sewell, MD, MPH
Jean Anderson, MD Catherine Sewell, MD, MPH To review diagnosis and management of HPV disease in the setting of HIV infection and address controversies HIV-infected women have: higher prevalence and incidence
More informationDisclosures & images
Cervical Cancer Screening: New Approaches Levi S. Downs, Jr., MD Disclosures & images During the previous 12 months, I have been a consultant for and received honoraria from Merck. Images are attributed
More informationSydney Gynaecology Oncology Group, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
bs_bs_banner doi:10.1111/jog.12545 J. Obstet. Gynaecol. Res. Vol. 41, No. 3: 440 444, March 2015 Abnormal cervicovaginal cytology, unsatisfactory colposcopy and the use of vaginal estrogen cream: An observational
More informationPrevalence and risk factors for cervical intraepithelial neoplasia among HIV-infected women
BRAZ J INFECT DIS. 2012;16(2):164-169 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Original Article Prevalence and risk factors for cervical intraepithelial neoplasia among
More informationPhilip E. Castle, Diane Solomon, Mark Schiffman, Cosette M. Wheeler for the ALTS Group
ARTICLEARTICLESHuman Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities Philip E. Castle, Diane Solomon, Mark Schiffman,
More informationCase Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure
Disclosure Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics This
More information(Pap) results, ie, abnormal squamous cells of undetermined significance (ASCUS). According to
The Role of Human Papillomavirus Type 16/18 Genotyping in Predicting High-Grade Cervical/Vaginal Intraepithelial Neoplasm in Women With Mildly Abnormal Papanicolaou Results Ming Guo, MD 1 ; Yun Gong, MD
More informationRESEARCH. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study
Short term of human papillomavirus and risk of cervical precancer and cancer: population based cohort study Philip E Castle, investigator, 1 Ana Cecilia Rodríguez, medical epidemiologist, 3 Robert D Burk,
More informationHKCOG GUIDELINES NUMBER 3 (revised November 2002) published by The Hong Kong College of Obstetricians and Gynaecologists
HKCOG Guidelines Guidelines on the Management of An Abnormal Cervical Smear Number 3 revised November 2002 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College of
More informationCervical Precancer: Evaluation and Management
TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of
More informationShould Anal Pap Smears Be a Standard of Care in HIV Management?
Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV
More informationClinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary
Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Glossary of Terms Colposcopy is the examination of the cervix, vagina and, in
More informationComparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic biopsy
Iranian Journal of Reproductive Medicine Vol.5. No.3. pp:121-126, Summer 2007 Comparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic
More informationNegative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
Anatomic Pathology / FALSE-NEGATIVE HISTOLOGIC FINDINGS Negative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
More informationHuman Papillomavirus (HPV) in Patients with HIV.
Human Papillomavirus (HPV) in Patients with HIV www.hivguidelines.org Purpose of the Guideline Increase the numbers of NYS residents with HIV who are screened for HPV-related dysplasia and managed effectively.
More informationWhat is cervical cancer?
What is cervical cancer? The cervix is the bottom part, or neck, of the uterus. Cervical cancer happens when normal cells in the cervix change into abnormal cells, and grow out of control. Most women whose
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 8 No ISSN 75 876 Findings and outcome of teenage women referred for colposcopy at Christchurch Women s Hospital, New Zealand Peter Sykes, Dianne Harker, David Peddie
More information